Home › NDC Lookup › RxCUI directory › RxCUI 310157

Erythromycin 500 MG Delayed Release Oral Tablet — RxCUI 310157

RxNorm drug concept · Semantic clinical drug
RxCUI 310157 Semantic clinical drug · SCD ● Current RxNorm concept 14 FDA products 29 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI310157
Official nameErythromycin 500 MG Delayed Release Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped14
Package NDCs mapped29
Reported Medicaid activity (SDUD)3,469 prescriptions · 22 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Erythromycin Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It's used to treat bacterial infections on the surface of your eye — the conjunctiva (the clear membrane over the white part) and the cornea (the clear front surface). It's also us...
  • What exactly does this eye ointment treat?
  • Gently pull your lower eyelid down to create a small pocket, then squeeze a ribbon of ointment — about 1 cm, roughly the size of a grain of rice — into that pocket. Blink a few tim...
  • How do I apply the ointment without making a mess?
📖 Read our full Erythromycin Ophthalmic guide →

🕸️ Concept Web — How Erythromycin 500 MG Delayed Release Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Erythromycin 500 MG Delayed Release Oral Tablet RxCUI 310157

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Erythromycin 4053
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ery-Tab 202609
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Erythromycin Delayed Release Oral Tablet 372060
    • Erythromycin Oral Product 1164504
    • Erythromycin Pill 1164505
    • Erythromycin Delayed Release Oral Tablet [Ery-Tab] 369801
    • Ery-Tab Oral Product 1168950
    • Ery-Tab Pill 1168951
    • Delayed Release Oral Tablet 10312
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Erythromycin 500 MG SCDC · 315877
  • Erythromycin Delayed Release Oral Tablet SCDF · 372060
  • Erythromycin Oral Product SCDG · 1164504
  • Erythromycin Pill SCDG · 1164505

Brand-Name Concepts

📦 FDA Products & Package NDCs

14 products · 29 package NDCs
29 package NDCs map to RxCUI 310157 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
13668-0586-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-586-01) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2021-07-26
13668-0586-05 500 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-586-05) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2021-07-26
13668-0586-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-586-30) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2021-09-21
13668-0587-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-587-01) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2024-10-21
13668-0587-05 500 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-587-05) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2024-10-21
13668-0587-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-587-30) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2024-10-21
13668-0588-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-588-01) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2021-07-26
13668-0588-05 500 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-588-05) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2021-07-26
13668-0588-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (13668-588-30) ERYTHROMYCIN Torrent Pharmaceuticals Limited 2021-09-21
24338-0122-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-122-03) ERY-TAB Arbor Pharmaceuticals, Inc. 2017-11-17
24338-0122-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-122-13) ERY-TAB Arbor Pharmaceuticals, Inc. 2011-04-18
24338-0124-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-124-03) ERY-TAB Arbor Pharmaceuticals, Inc. 2017-11-17
24338-0124-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-124-13) ERY-TAB Arbor Pharmaceuticals, Inc. 2011-04-18
24338-0126-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-126-03) ERY-TAB Arbor Pharmaceuticals, Inc. 2017-11-17
24338-0126-13 100 TABLET, DELAYED RELEASE in 1 BOTTLE (24338-126-13) ERY-TAB Arbor Pharmaceuticals, Inc. 2011-04-18
51407-0853-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (51407-853-30) ERYTHROMYCIN Golden State Medical Supply, Inc. 2023-12-07
51407-0854-30 30 TABLET, DELAYED RELEASE in 1 BOTTLE (51407-854-30) ERYTHROMYCIN Golden State Medical Supply, Inc. 2023-12-07
52536-0180-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (52536-180-03) Erythromycin Wilshire Pharmaceuticals 2019-07-22
52536-0180-10 100 TABLET, DELAYED RELEASE in 1 BOTTLE (52536-180-10) Erythromycin Wilshire Pharmaceuticals 2019-07-22
52536-0183-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (52536-183-03) Erythromycin Wilshire Pharmaceuticals 2019-07-22
52536-0183-10 100 TABLET, DELAYED RELEASE in 1 BOTTLE (52536-183-10) Erythromycin Wilshire Pharmaceuticals 2019-07-22
52536-0186-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (52536-186-03) Erythromycin Wilshire Pharmaceuticals 2019-07-22
52536-0186-10 100 TABLET, DELAYED RELEASE in 1 BOTTLE (52536-186-10) Erythromycin Wilshire Pharmaceuticals 2019-07-22
69238-1471-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1471-1) Erythromycin Amneal Pharmaceuticals NY LLC 2019-07-07
69238-1471-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1471-3) Erythromycin Amneal Pharmaceuticals NY LLC 2021-08-27
69238-1472-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1472-1) Erythromycin Amneal Pharmaceuticals NY LLC 2019-07-07
69238-1472-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1472-3) Erythromycin Amneal Pharmaceuticals NY LLC 2021-08-27
69238-1473-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1473-1) Erythromycin Amneal Pharmaceuticals NY LLC 2019-07-07
69238-1473-03 30 TABLET, DELAYED RELEASE in 1 BOTTLE (69238-1473-3) Erythromycin Amneal Pharmaceuticals NY LLC 2021-08-27
Observed labelers: Torrent Pharmaceuticals Limited (9) · Amneal Pharmaceuticals NY LLC (6) · Arbor Pharmaceuticals, Inc. (6) · Wilshire Pharmaceuticals (6) · Golden State Medical Supply, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.